Perspectives

Payer Perceptions of the Inflation Reduction Act

Lumanity convened medical and pharmacy directors from six large national and regional US payers with at least 25% Medicare business to share their perspectives on both the Maximum Fair Price (MFP) drug price negotiation and Part D redesign components of the IRA. Read the six key insights from our panel.

View Aug 28, 2023

Featured

Lumanity and the PHARMO Institute are partnering to deliver research insights

Resource Sep 20, 2023

ICER Value Assessment Framework Update 2023

Whitepaper Aug 31, 2023

The Transformative Potential of Digital Therapeutics in Mental Health Care Delivery

View Aug 24, 2023

The EU HTA Regulation

View Apr 27, 2023

Half-time in the EU HTA Regulation Roll Out

Whitepaper Sep 22, 2023

Before You Start the Strategic Planning Cycle: 5 essential things to streamline your approach

Whitepaper Sep 11, 2023

Pembrolizumab Receives NICE Approval for Five New Indications

Case Study Sep 6, 2023

ICER Value Assessment Framework Update 2023

Whitepaper Aug 31, 2023

Lumanity and the PHARMO Institute are partnering to deliver research insights

Download our fact sheets for additional details and information on our disease and treatment characterization, healthcare resource utilization, treatment patterns, burden of disease, clinical grouping, and comparative effectiveness, safety, and tolerability in these select indications.

Resource

Widespread Mental Health Provider Shortages Demand Innovative Options

View Aug 25, 2023

Policy Initiatives Can Improve Access to Prescription Digital Therapeutics

View Aug 25, 2023

The Transformative Potential of Digital Therapeutics in Mental Health Care Delivery

View Aug 24, 2023

Inflation Reduction Act (IRA): The Importance of Scenario Planning

View Aug 17, 2023

Medical Affairs Unscripted | Learning and Development to Propel an Organization Forward

In this discussion, Peg, Adeola Davis, PhD, MPA, Director of Learning Development at Acadia Pharmaceuticals, and Mary Winkels, PharmD, Global Director, Medical Affairs Training and Capability at Vertex Pharmaceuticals, break down what it takes to build a successful learning and development program and how to measure its success.

Podcast Sep 1, 2023

Advancing Clinical Development by Strategically Leveraging Advisory Boards

Whitepaper Aug 11, 2023

CAR T-Cell Therapies in the US, UK and EU4

Whitepaper Aug 8, 2023

Highlights from the 2023 ASCO Annual Meeting

Resource

Supporting an Emerging Pharmaceutical Company in the Development of a Drug for Pulmonary Sarcoidosis

Case Study Aug 1, 2023

The Growing Pipeline of First-Time Commercializers and the Challenges of New Enterprise Commercialization

Now that we are back from what is arguably the most important week in the life sciences calendar, we want to know what the sentiment is for fundraising in 2023 and will it get better in 2024.

On-Demand Webinar May 9, 2023

A Review of Product Claims and Packaging to Optimize Regulatory Compliance and Marketing Strategy

Case Study Aug 1, 2023

Developing a More Efficient Literature Monitoring Strategy to Inform Drug Development

Case Study Jul 31, 2023

Identifying Data Gaps to Support Positioning in Advance of a Pre-IND Meeting

Case Study Jul 31, 2023

Creating a Compelling Narrative to Guide the Pre-IND Meeting for a New Molecule

Case Study Jul 31, 2023